Schering-Plough Animal Health Corporation announced an agreement in which Schering-Plough Animal Health will acquire from Pfizer Inc. the U.S. distribution and marketing rights to Pfizer Animal Health's intramammary antibiotic infusion products Dariclox, Amoxi-Mast and Orbenin-DC.

Dariclox (sodium cloxacillin) and Amoxi-Mast (amoxicillin trihydrate) are approved by the U.S. Food and Drug Administration (FDA) for the treatment of mastitis (inflammation) in lactating dairy cattle. Orbenin-DC (benzathine cloxacillin) is approved by the FDA for the treatment and prevention of mastitis in non-lactating dairy cattle.

"The acquisition of these products expands Schering-Plough Animal Health's antibiotics product line and strengthens our presence in the livestock market," said Raul E. Kohan, president, Schering-Plough Animal Health.

Schering-Plough Animal Health expects to begin the distribution and marketing of the products in the United States by the end of April. Financial terms of the agreement are not being disclosed.